The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome

作者：Erwin S. Schultz, Jacques Chapiro, Christophe Lurquin, Stéphane Claverol, Odile Burlet‐Schiltz, Guy Warnier, Vincenzo E. A. Russo, Sandra Morel, Frédéric Lévy, Thierry Boon, Benoı̂t J. Van den Eynde, Pierre van der Bruggen · 发表于：The Journal of Experimental Medicine · 年份：2002 · DOI：10.1084/jem.20011974 · 被引用次数：122 · 研究领域：Immunotherapy and Immune Responses、Ubiquitin and proteasome pathways、vaccines and immunoinformatics approaches

By stimulating human CD8(+) T lymphocytes with autologous dendritic cells infected with an adenovirus encoding MAGE-3, we obtained a cytotoxic T lymphocyte (CTL) clone that recognized a new MAGE-3 antigenic peptide, AELVHFLLL, which is presented by HLA-B40. This peptide is also encoded by MAGE-12. The CTL clone recognized MAGE-3--expressing tumor cells only when they were first treated with IFN-gamma. Since this treatment is known to induce the exchange of the three catalytic subunits of the proteasome to form the immunoproteasome, this result suggested that the processing of this MAGE-3 peptide required the immunoproteasome. Transfection experiments showed that the substitution of beta5i (LMP7) for beta5 is necessary and sufficient for producing the peptide, whereas a mutated form of beta5i (LMP7) lacking the catalytically active site was ineffective. Mass spectrometric analyses of in vitro digestions of a long precursor peptide with either proteasome type showed that the immunoproteasome produced the antigenic peptide more efficiently, whereas the standard proteasome more efficiently introduced cleavages destroying the antigenic peptide. This is the first example of a tumor-specific antigen exclusively presented by tumor cells expressing the immunoproteasome.